Dasatinib inhibition of cSRC prevents the migration and metastasis of canine mammary cancer cells with enhanced Wnt and HER signalling

Elpetra P. M. Timmermans-Sprang | Helena M. Mestemaker | Renske R. Steenlage | Jan A. Mol

Department of Clinical Sciences of Companion Animals, Utrecht University, Utrecht, The Netherlands

Correspondence
Jan A. Mol, Department of Clinical Sciences of Companion Animals, Utrecht University, Yalelaan 104, 3584 CM Utrecht, The Netherlands.
Email: j.a.mol@uu.nl

Human epidermal growth factor 2 (HER2) overexpression leads to aggressive mammary tumour growth. Although the prognosis of HER2+ tumours in humans is greatly improved using biologicals, therapy resistance, which may be caused by increased phosphatidylinositol-3-kinase (PI3K), rous sarcoma proto-oncogene (cSRC) or wingless-type MMTV integration site family (Wnt) activity, is a major concern. A recent analysis of 12 canine mammary cell lines showed an association between HER2/3 overexpression and phosphatase and tensin homologue (PTEN) deletion with elevated Wnt-signalling. Wnt-activity appeared to be insensitive to phosphatidylinositol-3-kinase (PI3K) inhibitors but sensitive to Src-I1. We hypothesized that Wnt activation was caused by HER2/3-activated cSRC activation. The role of HER2/3 on Wnt signalling was investigated by silencing HER2/3 expression using specific small interfering RNA (siRNAs). Next, the effect of an epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor on Wnt activity and migration was investigated and compared to other tyrosine kinase inhibitors (TKIs) of related signalling pathways. Finally, two TKIs, a cSRC and a PI3K inhibitor, were investigated in a zebrafish xenograft model. Silencing of HER1-3 did not inhibit the intrinsic high Wnt activity, whereas the HER kinase inhibitor afatinib showed enhanced Wnt activity. The strongest inhibition of Wnt activity and cell viability and migration was shown by cSRC inhibitors, which also showed strong inhibition of cell viability and metastasis in a zebrafish xenograft model. HER2/3 overexpression or HER2/3-induced cSRC activation is not the cause of enhanced Wnt activity. However, inhibition of cSRC resulted in a strong inhibition of Wnt activity and cell migration and metastasis. Further studies are needed to...
unravel the mechanism of cSRC activation and cSRC inhibition to restore sensitivity to HER-inhibitors in HER2/3-positive breast cancer.

KEYWORDS

cSRC, dasatinib, HER2, mammary cancer, migration, Wnt

1 | INTRODUCTION

The life-time risk of mammary cancer is high not only in humans but also in dogs. Most of these carcinomas in both species are oestrogen receptor (ER) and progesterone receptor (PR)-positive and respond to endocrine therapy in humans. However, not all canine mammary tumours are well characterized, and immunohistochemical results may vary. Approximately, 15% to 20% of human breast cancers are characterized by a combination of human epidermal growth factor 2 (HER2) overexpression and a lack of steroid hormone receptors, leading to more aggressive tumour growth and a worse prognosis. Despite improved treatment options using therapeutic monoclonal antibodies against HER2, the acquisition of drug resistance remains a major problem and could lead to tumour recurrence. For triple negative carcinomas, no targeted therapy is available. HER2 overexpression in human breast cancer indicates a risk of recurrence independent of whether the axillary node is positive or negative for micrometastases. Overexpression of HER2 is often observed (50%) in ductal carcinomas. A clear role for HER2 overexpression in the progression from ductal carcinoma in situ (DCIS) to invasive carcinoma has not been shown, although dimerization of epidermal growth factor receptor (EGFR) and HER2 induces motility.

In human breast cancer, approximately, 50% of clinical samples have an elevated level of nuclear or cytoplasmic β-catenin, implicating active wingless-type MMTV integration site family (Wnt) signalling. In contrast to colon carcinomas, where mutations in adenomatous polyposis coli (APC) or β-catenin are the cause of activated Wnt signalling, these mutations are rarely found in breast cancer. Nevertheless, in human breast cancer, Wnt/β-catenin signalling has a clear contribution to tumour progression, metastasis, and a poor clinical outcome in all molecular subtypes of invasive breast cancer. In addition, HER2-mediated breast cancer progression requires β-catenin signalling; therefore, inhibition of Wnt signalling may be relevant in HER2-positive tumours. HER2 also acts among other pathways through the activation of rous sarcoma proto-oncogene (cSRC) kinases. Because we have shown that Wnt activity is sensitive to cSrc inhibition, we investigated the hypothesis that the enhanced expression of HER2/3 causes high Wnt activity through cSrc activation in some canine mammary tumour (CMT) cell lines.

Ductal carcinomas in dogs are comparable to the most common forms of human breast cancer. One-third of malignant mammary carcinomas in dogs may form life-threatening distant metastases. Tumour cells with cancer stem cell properties, such as a phenotypical epithelial-mesenchymal transition (EMT), can migrate and form metastases. In this regrowth and metastasis, elevated activity of the Wnt pathway plays an important role.

In a panel of 12 different canine mammary cell lines, we identified three cell lines in which the basal Wnt activity was highly elevated in a ligand-independent manner, as indicated by high T-cell-specific transcription factor (TCF) reporter activity. This Wnt activity was not caused by enhanced expression of Wnt ligands, whereas overexpression of lymphoid enhancer-binding factor 1 (LEF1) messenger RNA (mRNA) could only partially explain this elevated signalling. A rounded cell morphology characterized the cell lines, suggesting EMT. In general, EMT, which is characterized by alterations in cell shape and loss of attachment to other cells and the extracellular matrix (ECM), is caused by loss of E-cadherin expression. However, the cell lines with high Wnt activity and rounded cell morphology had relatively high E-cadherin expression, excluding the likelihood that loss of E-cadherin caused high canonical Wnt activity and elevated β-catenin levels.

Further analysis by quantitative polymerase chain reaction (qPCR) of selected genes showed that the cell lines with high Wnt signalling overexpressed HER2,3 mRNA with LEF1, heat shock protein 90 (HSP90) and ras-like protein (RAC1), among others, and silenced phosphatase and tensin homologue (PTEN) mRNA expression. The loss of PTEN expression in combination with an increased expression level of HER3, which promotes HER2-driven mammary tumour proliferation, could indicate a highly activated PI3K/mammalian target of rapamycin (mTOR) pathway. However, inhibition of this pathway with the mTOR inhibitor everolimus or the dual PI3K/mTOR inhibitor BEZ235 further upregulated the already basal activated Wnt activity. Wnt activity could only be inhibited by Src-11, a tyrosine kinase inhibitor that targets cSRC, among others. Recently, SRC has been shown to promote resistance to trastuzumab in HER2-positive breast cancer. Uptregulation of cSRC stabilizes HER2 and vice versa. However, to the best of our knowledge, no literature is available on HER2/3 activation of Wnt signalling through cSRC activation.

HER signalling occurs predominantly by activating the PI3K/AKT/mTOR pathway, but HER dimers may also transduce signals through cSRC/focal adhesion kinase (FAK) complexes. These complexes influence the Wnt pathway by interacting with β-catenin. Therefore, it is likely that a connection exists between Wnt, cSRC and HER signalling. Considering that cSRC could be activated by EGFR and HER2/3, this likely makes cSRC a key player in the activation of highly activated basal Wnt cells.
The central role of cSRC signalling was further investigated in vitro by cell migration and invasion assays and in an in vivo zebrafish embryo xenograft model. This model has been validated extensively, showing that short-term experiments in zebrafish embryos correlate well with long-term rodent xenograft models of breast cancer cell lines with variable grades of malignancy. In general, dye-labelled cells are injected into the yolk sac, followed by invasion into the blood stream and the formation of distant metastases. However, cells may also be inserted directly into the blood stream through injection into the duct of Cuvier to investigate metastatic properties of breast cancer cell lines. This model has also been validated in our laboratory for human insulinoma cell line metastasis and compared to xenografts in mice. The same model was used for investigating the effects of mTOR and cSRC inhibition on the metastatic properties of cells with high Wnt signalling in the current study. For cSRC inhibition, dasatinib was used because this selective cSRC inhibitor is FDA-approved.

The aim of this study was to investigate the role of HER signalling in enhanced canonical Wnt signalling and to investigate tyrosine kinase inhibitors (TKIs) related to HER signalling as inhibitors of Wnt activity and associated cell migration and metastasis.

2.2 | Small interfering RNA

Canine sequence-specific EGFR (GenBank: XM_533073), HER2 (GenBank: NM_001003217) and HER3 (GenBank: XM_538226) siRNA was designed on the website http://rnaidesigner.thermo Fisher.com (Thermo Scientific, Breda, The Netherlands). Universal MOCK siRNA (ON-Target and the non-targeting pool species H (human), M (mouse) and R (rat) (Thermo Scientific) were used as negative controls for the siRNA experiments. There was no cross-silencing of non-target genes, which was verified by BLASTing the designed siRNA sequences against the canine genome database. The sequences of the siRNA duplexes were as follows: EGFR sense 3236 CCGUCUCAUCAACAGGCCUCUAAA and antisense UUUAGAGGCUGAUUGUGUA and antisense UUCACAAUCCCAUCAUGGUCUCG. Cell transfections were first optimized with siGLO (Dharmacon, Colorado) (data not shown). A total of 125 000 CMT-U27 cells were transfected with 3 μM Lipofectamine 2000 (Invitrogen) transfection reagent, 50 nM siRNA and 0.8 μg DNA in 24-well Primaria plates (Corning, New York). After 24, 48 and 72 hours incubation in DMEM/F12 and 10% FCS, the cells were harvested for RNA isolation, protein isolation and a transcription factor (TCF)-reporter assay.

2.3 | RNA isolation, cDNA synthesis and quantitative RT-PCR

RNA was isolated at 24, 48 and 72 hours after transfection using an RNeasy Mini kit (Qiagen, Venlo, The Netherlands) according to the manufacturer’s protocol with a DNAse (Qiagen) treatment. cDNA synthesis was performed using an iScript kit (Bio-Rad, Veenendaal, The Netherlands) according to the manufacturer’s protocol. Specific primer sets were used to amplify the gene products for quantitative PCR (qPCR) (Table 1). qPCR was performed using Bio-Rad CFX manager software (version 3.1) with a SYBR Green fluorophore (Bio-Rad). Relative target gene expression was normalized to a set of seven reference genes and analysed by the geNorm implementation of the SLCqPCR package in R using RStudio (version 3.3.1) with a pairwise variation (PV) of 0.07. Relative expression was calculated by the ΔΔCt method and the relative induction of gene expression was statistically analysed using SPSS (version 24).

2.4 | Protein isolation and Western blot

CMT-U27 cells were seeded at a density of 600 000 in 6-well Primaria plates (Corning) and transiently transfected with the siRNA after 24 hours. After 24, 48 and 72 hours, the cells were washed with Hank’s balanced salt solution (Invitrogen) and lysed and scraped with RIPA buffer. Twenty micrograms of protein from the total cell lysate was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and analysed by Western blot. The primary antibodies used were against EGFR (Ab2430, 1:200 dilution) (Abcam, Cambridge, UK), HER2 (PA-14635, 1:500 dilution) (Thermo Scientific), HER3 (PA1-86644, 1:2500 dilution) (Thermo Scientific) and β-Actin pan Ab-5 (MS-1295-P1, 1:2000 dilution) (Thermo Scientific) as a loading control. Goat anti-rabbit Horseradish peroxidase (HRP)-conjugated (HAF008) and donkey anti-goat HRP-conjugated (HAF109) (R&D Systems, Abingdon, UK) secondary antibodies were used at a 1:20000 dilution. HRP was visualized using Advance enhanced chemiluminescence (ECL, GE Healthcare, Eindhoven, The Netherlands) and analysed using GelDoc 2000 (Bio-Rad).
| OMIM accession | Symbol | Forward primer | Reverse primer | Ta (°C) | Size (bp) | Number |
|----------------|--------|----------------|----------------|---------|-----------|--------|
| **Target genes** |        |                |                |         |           |        |
| AXIN2          | Axin2  | GGACAAATGCGTGGATACCT | TGCTTGGAGAAGACATGTT | 60      | 128       | XM_54802 |
| APC            | APC    | AAGCTCAAGAAGCAAGACG | GCAAGTGGACCTCTGAGCA | 63      | 138       | XM_536285 |
| CTNNB1         | βCatenin | ATGGGTAGGGCAAATCAGTAAGAGG | TAAGCATCGATCACACGATGTTAC | 64      | 106       | NM_005634157.1 |
| BNIPL          | Bcl2   | TGGAGAGCGTCAACCGGGAGATGT | AGGATGTGGCAGATCCGGTTACAGGT | 62      | 87        | AY_509563.1 |
| CDH1           | ECAD   | CAGAAGGCTACTCCAGCAAGAG | CGTGGGAAAGGTAGGACACCTC | 58      | 105       | NM_001287125.1 |
| CCND1          | CyclinD1 | GCTCTGAAGATGAAAGGACGAC | CGATTGTTCTACAGAGAGGAC | 60      | 117       | NM_001005757.1 |
| ERBB1          | EGFR   | CTGAGAAGACTGCCGAAGCA | TGGCTTTGGGGAGACAGG | 53      | 107       | XM_533073 |
| ERBB2          | HER2   | AGTGGAGGAATGGTGGCAGAC | AGATCCCTGTGGCAGATGCC | 64      | 121       | XM_545629 |
| ERBB3          | HER3   | TGGTGTGCTCTTTCACCTGTG | GGTCTTGGTCAATGTCTGGCAT | 70      | 103       | XM_538226 |
| ERBB4          | HER4   | CAGTTCCTCTTGTTGCGTCTG | AGTGTGTCCTCTCTGAAAGG | 64      | 114       | XM_54629 |
| HSP90AA1       | HSP90  | CTTGAGCCATCGCCCAAGATTAGC | TATTGATCAGGTCGGCCAGAA | 59      | 127       | XR_134513.2 |
| ID1            | ID1    | CTCACACCGAGGAGATGAG | GACAGGGGTGTTCTCTC | 59.5    | 135       | XM_847117.2 |
| ID2            | ID2    | GCTGAAATAAATGGTGTTCG | GTTGTTCTCCTTGTGAAATGG | 60.5    | 114       | XR_134413.1 |
| LGR5           | LGR5   | CTCACCGCTCTCCACCTCTCTC | TGGAAGATGTATGCTAAAACGCT | 67      | 115       | XM_846738.2 |
| MET            | cMET   | TTGTGCTGTTGTAACCTGTAGATG | ATGGATGATGGCTGCGTTCACTG | 56      | 159       | NM_001002963.1 |
| MUC1           | MUC1   | AGACATCGCTCCAGCCCGAGAAC | GAAAGATGAGTAGACCTGGATGAC | 59      | 137       | NM_00194977 |
| NCOA1          | NCOA1  | GGAACACGACGAAATAGCAGCATAC | TAATCCGCGTGCAATACAAATCAGCA | 67.1    | 189       | XM_532891.5 |
| NRG1           | NRG1   | CATTGGCCCTGTCTTGGTCTG | GTGTGATGGCGCCCTTGTTCTAG | 67      | 144       | XM_853054.3 |
| PGR            | P | CAAATGGAAGGAGACAACTAACC | CAGCATTTCTAAGGCGACA | 57      | 102       | NM_001003074.1 |
| PLCB4          | PLCB4  | CCAATCGAGATGATTTACTAGAGCTA | AAAAGATCCCTCTTATCTGTCGG | 64.5    | 184       | XM_854626.3 |
| CDH3           | PCAD   | GCCCGCGCTACTAGACATCCATATT | GAAGGGCGTGCCCCTGTCG | 67      | 137       | XM_005620790.2 |
| RAC1           | Rac1   | CTCCTATATCATATGCCAA | ATGATAGGCGGTGCTGAGGAG | 58      | 128       | NM_001003274.2 |
| Rac1b          | Rac1b  | TGGAAATACGCTGGAAGACA | CGTGTTCCTGCTCTGAGGA | 58      | 108       | JN_182651.1 |
| SNAI2          | SNAI2  | CTCTGAGAAGGGGAGTGGTGGGAA | TGCCCAAGATGCTGATACAGAGA | 66      | 134       | XM_544774.5 |
| SRC            | cSRC   | CATTGGGAAGGGGAGTTTGGGAGA | TGCCGAAGATGCTGATACAGAGA | 66      | 134       | XM_544774.5 |
| TGFA           | TGFr   | CCGCTTTGTGTTGTTGCTTCC | AGGCGCTGGCTTCTGCTCA | 61      | 83        | NM_001003244.4 |

| Reference genes |        |                |                |         |           |        |
|-----------------|--------|----------------|----------------|---------|-----------|--------|
| HNRNPH2         | HNRPH  | CTCATCTATGATGAACTCAC | TAGATCCCTCAAGACTCCACAG | 61.2    | 151       | XM_538576 |
| RPL13           | RPL13  | GCGGGAAGGTGTGCTGCTG | GGAAGGAAGCCGAGTAATTC | 61      | 87        | XM_00432726 |
| RPS5            | RPS5   | TGGCCTTGGTGAGGAGGCCCT | CTGGATTACGCAGGCTGAT | 62.5    | 141       | XM_533568 |
| RPS19           | RPS19  | CTTTTCTCCCIIIATATGTCGG | GTCTTGTGCATAGGACGAC | 62      | 95        | XM_533567 |
| SDHA            | SDHA   | GCCGCGTTACTCTGTGATG | GTCTGTTGCTCGAGTACG | 61      | 92        | DQ042985 |
| TBP             | TBP    | CTTATTTTCGGTCTGACAGGA | CTCGGGAATCCAGTCCTTTTC | 57      | 96        | XM_849432 |
| YWHAZ           | YWHAZ  | CGGAAGGGCTCGTTGGGA | TGCTATGTTGGCTCTGCTCA | 58      | 96        | XM_843951 |

Abbreviations: APC, adenomatous polyposis coli; Axin 2, axis inhibitor 2; Bcl-2, B-cell leukaemia 2 oncogene; CCND1, cyclin D1; CDH, cadherin; cMET, tyrosine-protein kinase Met (or HGF) proto-oncogene; cSRC, rous sarcoma proto-oncogene; Cyclin D1, cyclin D1; EGFR, epidermal growth factor receptor; ERBB, human epidermal growth factor receptor; ERBB1, epidermal growth factor receptor; FYN, FYN oncogene related to SRC, FGR, YES; HNRPH, heterogeneous nuclear ribonucleoprotein H; HSP90, heat shock protein 90; ID1/2, inhibitor of DNA binding 1/2; LEF1, lymphoid enhancer-binding factor 1; LGR5, low-density-lipoprotein related protein; MUC1, mucin 1; NCOA3, nuclear receptor coactivator; NRG1, neuregulin, heregulin-alpha; PR, progesterone receptor; PLCB4, phospholipase C beta-4; RAC1, ras-like protein; RPL13, ribosomal protein L43; SDHA, succinate dehydrogenase complex subunit A; SNAI2, SNAIL; TBP, TATA-box binding protein; TCF, T-cell-specific transcription factor.
Table 2: IC-50 values

| Inhibitor | Target | CMT-U27 (µM) | CIPm (µM) |
|-----------|--------|--------------|-----------|
| Aftatinib | EGFR + HER2 | 22 | 69 |
| Aurora A | Aurora A | 1 | 13 |
| AZD1480 | JAK2 | 28 | 9 |
| AZD7762 | CHK1 + CHK2 | 301 | 1 |
| Barasertib | Aurora A + B | 77 | 822 |
| Dasatinib | SRC | 17 | 23 |
| OSI-906 | IGF-1R | 18 | 54 |
| PP2 | LCK + FYN | 41 | 70 |

Abbreviations: CHK1/2, cell cycle checkpoint kinase 1/2; CMT, canine mammary tumour cell line; IGF-1, insulin-like growth factor 1 (receptor); JAK2, Janus kinase 2; LCK, lymphocyte specific protein-tyrosine kinase; mammary tumour cell line; IGF-1, Rinsulin-like growth factor 1 (receptor); Abbreviations: CHK1/2, cell cycle checkpoint kinase 1/2; CMT, canine mammary tumour cell line; IGF-1, insulin-like growth factor 1 (receptor); JAK2, Janus kinase 2; LCK, lymphocyte specific protein-tyrosine kinase; mammary tumour cell line; IGF-1, insulin-like growth factor 1 (receptor); PP2, inhibitor for cSRC-family kinases.

2.5 | TCF reporter assay

Cells were seeded in a 24-well Primaria plate (Corning) at a density of 100 000 CMT-U27 cells/well and allowed to reach 80% confluency 24 hours before transfection. Transfection was performed in FBS-free medium using 3 µL Lipofectamine 2000 (Invitrogen), 800 ng pTOPFLASH (TOP) or pFOPFLASH (FOP) (a gift from Prof. Dr. Hans Clevers, Hubrecht Institute, The Netherlands) and 0.5 ng pTOPFLASH (TOP) or pFOPFLASH (FOP) (a gift from Prof. Dr. Hans Clevers, Hubrecht Institute, The Netherlands) and 0.5 ng human β-actin promoter Renilla construct as an internal control. The half-maximum inhibitory concentration (IC50) of the inhibitors was analysed by an MTT assay, and the cells were treated with the IC50 concentration of the inhibitors (Table 2). All compounds were dissolved in dimethyl sulfoxide (DMSO) and diluted in medium. A final concentration of 0.2% DMSO was used as a control. The firefly and Renilla luciferase activities were analysed using a Dual-Luciferase Assay System (Promega, Leiden, The Netherlands) in a Centro LB 960 luminometer (Berthold Technologies, Vilvoorde, Belgium).

2.6 | Cell viability

Cell viability was analysed by a colorimetric 3-[4,5-dimethylthiazol-2-yl] 2,5-diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich, Zwijndrecht, The Netherlands). Briefly, cells were seeded in 96-well Primaria plates (Corning) at a density of 15 000 cells/well (for CMT-U27 cells) and 10 000 cells/well (for CIPm cells) in DMEM/F12 with 10% FBS. After 24 hours of incubation cell adhesion and spreading, the cells were treated with the following eight inhibitors: afatinib, Aurora A inhibitor I, AZD1480, AZD7762, barasertib, dasatinib, OSI-906 and PP2 (inhibitor for cSRC-family kinases) (all from Selleck Chemicals, Munich, Germany). The inhibitors had different susceptibilities to different kinase pathways and were dissolved in DMSO to a final stock concentration of 10 mM. The inhibitors were added in a concentration range from 1 nM to 1 mM diluted in medium to a final concentration of 0.2% DMSO and incubated for 48 hours. The absorbance was measured at a wavelength of 595 nm by an Anthos Multimode Detector spectrophotometer (Anthos Mikrosystem GmbH, Krefeld, Germany). IC50 curves were plotted with Sigma Plot version 12.5.

2.7 | Cell migration

Cells were seeded in 6-well Primaria plates (Corning) at a density of 1 000 000 cells/well (for CMT-U27 cells) and 500 000 cells/well (for CIPm cells). After 24 hours, the monolayer of cells was scraped with a 200 µL pipette tip to create a straight gap. The medium was removed, and the cells were washed with Hank’s balanced salt solution (HBSS) (Invitrogen). The cells were treated with 100 nM everolimus (Selleck Chemicals), 50 nM BEZ235 (Selleck Chemicals), 20 µM SRC-11 (Enzo, Lausen, Switzerland) or 10 µM PP2 (Selleck Chemicals). At 0, 24 and 48 hours, cells migrating into the scratched area were imaged with an Olympus microscope (Olympus, Tokyo, Japan) and analysed with ImageJ software version 1.47. The closure of the gap was calculated as follows: percentage of scratch closure = a−b/a, where a is the distance of the gap at t = 0, and b is the distance of the gap at t = 24 or 48 hours.

2.8 | Cell Invasion

A 3D chemotaxis µ-slide (Ibidi GmbH, Munich, Germany) and DMEM/F12 medium (Invitrogen) were pre-equilibrated for 24 hours at 37°C before use. CMT-U27 and CIPm cells were resuspended at 300000 cells/100 µL DMEM/F12 with 1 mg/mL collagen-I gel solution (rat tail collagen, Sigma-Aldrich). Six microlitres of the collagen gel containing cell suspension was quickly seeded into the central chamber of the 3D chemotaxis µ-slide. The slides were incubated upside down for 1 hour at 37°C in an incubator. Then, the reservoirs were filled with 70 µL DMEM/F12 (left side of the collagen cell suspension) or with DMEM/F12 with FCS as a chemoattractant and with or without dasatinib as an inhibitor (10 µM final concentration, Selleck Chemicals) (right side). The slides were incubated for 22 hours in a humidified Petri dish at 37°C. The cells were then stained with 2.5 µg/mL calcein AM (Invitrogen) dissolved in DMSO and diluted 1000x in Hank’s balanced salt solution (Invitrogen) for 1 hour. After 3 washes with Hank’s balanced salt solution, the fluorescence of the cells was analysed with a Leica SPE-II microscope.

2.9 | Xenograft

To investigate the effect of inhibition of cSRC or PI3K signalling on the metastasis of canine mammary cells, a xenograft model in zebrafish was used that has been validated previously and has been used in our laboratory to investigate the metastasis of canine insulinoma cells. The transgenic zebrafish line Tg(fli1:GFP) was used for the xenograft experiments. The zebrafish were raised and maintained according to standard procedures.
Dechorionized 2-day-post-fertilization zebrafish embryos were anaesthetised with 0.003% tricaine (Sigma-Aldrich) and positioned on a 10-cm Petri dish coated with 1% agarose. Single cell suspensions of CMT-U27-RED (pHAGE2-EF1a-DsRed-PuroR) cells were resuspended in 2% polyvinylpyrrolidone (Sigma-Aldrich) in Hank’s balanced salt solution (200 cells/nL) and were implanted within 1 hour, as reported previously. The zebrafish embryos were either injected with 2 nL CMT-U27 RED cell suspension or with 2 nL CMT-U27 RED cell suspension containing 10 μM dasatinib or 10 μM everolimus. To investigate the compound in the zebrafish, dasatinib was added to E3 medium (0.1 μM). Three and 5 days post-injection (dpi), the embryos were analysed with confocal fluorescence imaging techniques. CMT-U27 RED cells were injected in the yolk sac or in the duct of Cuvier. Cells injected into the yolk sac have to migrate to the blood circulation before they may form distant metastases, whereas direct injection into the bloodstream using the duct of Cuvier does not require intravasation and can form distant metastases more easily.

The embryos were directly inspected for proper injection and were fixed on day 3 or 5 (dpi) and imaged under a confocal microscope. The experiments were performed in triplicate with 30 to 40 well-injected embryos for dasatinib and 10 embryos for the everolimus experiments. The survival rate at 1 dpi was >90% in each experiment. The localization of tumour cells and the percentages of embryos with metastasis were manually scored.

2.10 | Statistics

Statistical analysis was conducted using IBM SPSS Statistics version 22 and 24 software (SPSS Benelux, Gorinchem, The Netherlands). The data were normally distributed; therefore, one-way analysis of variance and post hoc Bonferroni tests were used. Compared to the DMSO control group, P < 0.05 was considered significant, indicated with an asterisk (*) for the Wnt activity (n = 3*4) and for the scratch assay results. The gene expression results from the siRNA experiments were analysed using a nonparametric test in SPSS (version 24) against the MOCK group (n = 6); *P < 0.01. The number of zebrafish embryos was scored for cell survival and distant metastases. The results were statistically analysed with Fisher’s exact test (Microsoft Excel).
Excel version 2010), and \( P < 0.01 \) was considered to be significant (\( n = 10-40 \) embryos for each condition).

3 | RESULTS

3.1 | Silencing of HER mRNAs

Three out of 12 canine mammary cell lines had highly elevated ligand-independent basal Wnt activity. These cell lines were also shown to have relatively high expression levels of EGFR, HER2 and HER3 mRNA compared with the other cell lines. The question is whether this is only an association or whether overexpression of HER proteins is a direct cause of Wnt pathway activation. We used the well-described CMT-U27 cell line for the studies. Treatment with various siRNAs resulted in a time-dependent decrease in the mRNA expression levels of EGFR, HER2 and HER3 (Figure 1A). Knockdown with EGFR siRNA resulted not only in significant downregulation of EGFR mRNA expression but also in lower levels of HER2 mRNA expression after 24 hours. The siRNA against HER2 resulted in fast downregulation of all three mRNAs, whereas the siRNA against HER3 was observed to be selective at 24 hours; but after longer incubation times, the mRNA expression of EGFR and HER2 were also significantly inhibited (Figure 1A). The combination of siRNA against HER2 and HER3 resulted in substantially decreased mRNA expression levels for all three receptors. However, despite the strongly decreased mRNA expression levels, no inhibition of basal Wnt activity, which was indicated by the TOP/FOP-luciferase reporter activity, was observed after 48 or 72 hours compared with the mock incubations (Figure 1B). The lack of the effect was not caused by stable protein expression, because Western blot analysis after 72 hours also showed decreased expression levels in the protein bands (Figure 1C). Additional analysis of various Wnt target genes even showed limited increases in the mRNA expression levels of axis inhibitor 2 (AXIN2), LEF1, low-density-lipoprotein related protein (LGR5) and SRC after 72 hours (Figure S2 siRNA qPCR).

3.2 | Cell proliferation, Wnt activity, migration and invasion in vitro

Previous research has shown that the high Wnt activity in three cell lines is sensitive to inhibition by the TKI Src-I1, leading to the hypothesis that increased HER-mediated cSRC activity causes elevated Wnt activity. Therefore, we investigated the effect of EGFR and the HER2 TKI afatinib with a variety of related TKI inhibitors on cell proliferation, Wnt activity and migration of CMT-U27 cells with high Wnt activity and CIPm cells with low Wnt activity. All TKIs inhibited cell proliferation in a dose-dependent manner (Figure S1 IC50) with IC50 values in the \( \mu \)M range (Table 2). No differences in cell viability were observed between CMT-U27 and CIPm cells in the 0.2% DMSO control compared with medium. In general, CMT-U27 cells were slightly more sensitive to inhibition than CIPm cells.

**FIGURE 2** The effect of tyrosine kinase inhibitor (TKIs) on wingless-type MMTV integration site family (Wnt) activity. The effects of canine mammary tumor cell line (CMT)-U27 cells after incubation for 48 hours with tyrosine kinase inhibitors on wingless-type MMTV integration site family (Wnt) signalling analysed by TOP/FOP luciferase reporter activity. The epidermal growth factor receptor (EGFR) inhibitor afatinib stimulated Wnt activity 3.5-times. The Aurora B and A inhibitor barasertib, the lymphocyte specific protein-tyrosine kinase (LCK) and FYN inhibitor PP2 (inhibitor for rous sarcoma proto-oncogene [cSRC]-family kinases), and the cSRC inhibitor dasatinib significantly downregulated Wnt reporter activity. The mean ratio of three independent experiments is shown. *\( P < 0.05 \) vs the control

| compound     | target                      | TOP/FOP ratio |
|--------------|-----------------------------|---------------|
| DMSO         | control                     |               |
| afatinib     | EGFR and HER2               | *             |
| AZD7762      | CHK1 and 2                  | *             |
| aurora A inhibitor | Aurora A, B and C | *             |
| barasertib   | Aurora B, and A             | *             |
| AZD1480      | JAK 2                       |               |
| OSI-906      | IGF-1R                      |               |
| PP2          | LCK and FYN                 | *             |
| dasatinib    | SRC                         | *             |
Remarkably, the high basal Wnt activity in the HER2/3-overexpressing CMT-U27 cells was further stimulated by the EGFR and HER2 inhibitor afatinib (Figure 2). Consistent with previous results, significant inhibition of Wnt activity was observed with the Src family of tyrosine kinase (SFK) inhibitors, including PP2 and dasatinib. The inhibitors PP2 and Src-I1 also showed strong inhibition of CMT-U27 cell migration in a scratch assay together with inhibitors of the PI3K pathway (Figure 3 A, C). None of the investigated inhibitors affected the migration of the control CIPm cells (Figure 3 B, D). The scratched gaps were filled completely within 48 hours, and there was no significant difference in the migration rate. Both cell lines moved through the collagen towards the chemoattractant in the invasion assay (Figure 4A), where CMT-U27 cells were further from the border of the matrix than the CIPm cells (Figure 4B, D). Dasatinib completely inhibited the invasion of CMT-U27 cells and partially inhibited the invasion of CIPm cells (Figure 4(C), (E)).

### 3.3 The effect on metastasis in vivo

Finally, the effects of PI3K/mTOR or cSRC inhibition on the metastatic properties of the CMT-U27 cell line were investigated in a zebrafish embryo xenograft model that was previously validated in our laboratory and used in this study because of the 3R principle (reduction, refinement and replacement) of animal use in biomedical research. Because the PI3K/mTOR inhibitor everolimus and the cSRC inhibitor dasatinib are used in clinical trials for humans with advanced breast cancer, they were used in this study.

Most of the zebrafish embryos survived the injection with DsRed-labelled CMT-U27 cells (CMT RED), with 76% survival after yolk sac injection and 80% survival after injection into the duct of Cuvier. Pre-treatment of CMT-U27 cells with 1 μM dasatinib before xenografting greatly reduced both cell survival and the number of larvae with clearly visible metastases (Figure 5) at 3 and 5 days post injection.
This was observed after injection in the yolk sac and after direct injection in the blood stream, where more metastases were observed without preincubation. Even when dasatinib was added to the egg medium, no metastases were observed (not shown).

When CMT RED cells were injected into the yolk sac in the presence of everolimus, the number of metastases increased (Figure 6). More clumps of tumour cells were observed when CMT RED cells were injected in the duct of Cuvier, extravasation of the CMT RED cells was observed and everolimus slightly increased the amount of metastases.

4 | DISCUSSION

In the present study, we investigated our hypothesis that overexpression of HER2/3 is related to the ligand-independent high basal Wnt activity of canine mammary cancer cells through the activation of cSRc (Figure 7).

Activation of Wnt signalling is related to the stemness and migration of cells, suggesting that inhibition of Wnt activity could play a central role in reducing or even preventing breast cancer metastasis in some cases. Therefore, we investigated the underlying cause of the high basal Wnt activity in the CMT-U27 metastatic canine mammary cell line, which was selected from a panel of canine mammary cell lines where 3 out of 12 cell lines were characterized by high ligand-independent Wnt signalling. Additional studies showed that these cell lines had HER2/3 overexpression, absent PTEN mRNA, and sensitivity to Src-I1, indicating a possible relationship between HER signalling and Wnt activity. However, in the present study, we were unable to show a direct relation by silencing HER protein expression with siRNAs. The knockdown percentages were greater than 50% for all tested siRNAs. EGFR, HER2 and HER3 and the combination of
HER2 + 3 had decreased mRNA expression levels at 24 hours and decreased protein expression levels after 72 hours for all tested siRNAs. Nevertheless, these decreased expression levels were not accompanied by decreased Wnt activity, as indicated by a TCF reporter assay of target genes. There was no knockdown effect of EGFR or HER2/3 on WNT target genes, such as β-catenin, AXIN2 and cyclin D1. Even when the β-catenin mRNA expression level decreased after HER3 silencing, there was no inhibition of Wnt activity. Enhanced mRNA expression of LGR5 and LEF1 was observed after knockdown of the HER proteins, although this did not result in an increased TOP/FOP ratio or cyclin D1 expression. Rather, the slight upregulation of AXIN2 mRNA expression indicated limited stimulation of the Wnt pathway. Resistance to inhibition with the HER2 monoclonal antibody trastuzumab in HER2+ human breast cancer is related to HER3 expression and activation, implicating a key role for HER3. However, according to our experiments, this did not seem to be related to active Wnt signalling. Recently, we showed that HER3 protein expression could be inhibited with the TKI Src-I1 in CMT-U27 cells, together with inhibition of elevated Wnt activity. From our siRNA experiments in this study, we concluded that the reduction in Wnt activity is not caused by the decreased HER3 expression level.

**FIGURE 5** The effect of the rous sarcoma proto-oncogene (cSRC) inhibitor dasatinib in zebrafish embryos. The effect of the cSRC inhibitor dasatinib on xenografted DsRed-labelled canine mammary tumor cell line (CMT)-U27 cells in zebrafish embryos. Three days post-injection (3 dpi) in the yolk sac of untreated cells (A) cell proliferation in the yolk sac and cells in the tail veins were observed, whereas 10 μM dasatinib-treated cells (B) remained in the yolk sac. At 5 dpi for the control cells (C), further yolk sac proliferation and clear extravasation in the tail veins were observed, whereas after dasatinib pretreatment, only limited survival in the yolk sac was observed (D). When the control cells were directly injected in the duct of Cuvier at 3 dpi (E) tumorous masses were observed to have formed in the tail veins, and extravasation was observed near the heart, which is an effect that was not observed in dasatinib-treated cells (F). At 5 dpi, tumorous masses of control cells were extended (G), whereas only some of the dasatinib-treated cells (H) ended in the tail veins but did not form tumorous masses. Statistical analysis was performed (I, J) using Fisher’s exact test. *P < 0.05 was considered significant [Colour figure can be viewed at wileyonlinelibrary.com]

![Graph showing incidence of metastasis](image-url)
Therefore, we investigated a panel of related TKIs to find a connection between cSRC, Wnt and EGFR signalling. Afatinib, a small molecule inhibitor of HER signalling, upregulated Wnt activity, most likely through inhibition of PI3K/mTOR activity, and we have also observed this with the mTOR inhibitor everolimus in the same cell line. Therefore, it is highly unlikely that HER signalling plays a role in the activation of the Wnt pathway.

**FIGURE 6** The effect of the phosphatidyl-3-kinase (PI3K) inhibitor everolimus in zebrafish embryos. The effect of the mammalian target of rapamycin (mTOR) inhibitor everolimus on xenografted DsRed-labelled canine mammary tumor cell line (CMT)-U27 cells in zebrafish embryos. Three days post-injection (3 dpi) of untreated cells in the yolk sac (A) cell proliferation in the yolk sac and cells in the tail veins were observed, whereas after pre-treatment with 10 μM everolimus (B), even more CMT RED cells were observed, indicating that the cells survived, proliferated and intravasated (arrows). Additionally, extravasation was more pronounced when CMT RED cells were directly injected into the circulation through the duct of Cuvier (C), showing tumour cells that formed a clump halfway through the tail, and the cells with everolimus resulted in tail vein tumours and extravasation (D). Statistical analysis was performed using (E, F) Fisher's exact test. *P < 0.05 was considered significant [Colour figure can be viewed at wileyonlinelibrary.com]

**FIGURE 7** Interacting pathway scheme. The cell lines with high basal wingless-type MMTV integration site family (Wnt) activity are also characterized by human epidermal growth factor 2/3 (HER2/3) overexpression, high E-cadherin expression levels and loss of phosphatase and tensin homolog (PTEN) expression. The question is whether stimulation of the phosphatidylinositol-3-kinase (PI3K) pathway is involved in enhancing Wnt signalling through rous sarcoma proto-oncogene (cSRC) activation [Colour figure can be viewed at wileyonlinelibrary.com]

0.18 μM, which is far below the concentration that we used. Therefore, we investigated a panel of related TKIs to find a connection between cSRC, Wnt and EGFR signalling. Afatinib, a small molecule inhibitor of HER signalling, upregulated Wnt activity, most likely through inhibition of PI3K/mTOR activity, and we have also observed this with the mTOR inhibitor everolimus in the same cell line. Therefore, it is highly unlikely that HER signalling plays a role in the activation of the Wnt pathway.
The cSRC inhibitors dasatinib and PP2 decreased Wnt activity in CMT-U27 cells. Both dasatinib and PP2 target members of the SRC family of protein kinases (SFK), including SRC, LYN and FYN. Activated SRC can stimulate the canonical Wnt pathway by phosphorylating Dishevelled \(^2\)\(^{,62,63}\), phosphorylating β-catenin,\(^64\) enhancing the synthesis of β-catenin,\(^65\) or interacting with β-catenin.\(^66\) Increased Wnt/β-catenin activity leads to elevated SLUG (SNAIL) expression that promotes EMT.\(^67\) As expected, inhibition of Wnt activity resulted in the inhibition of the invasive and migratory ability of CMT-U27 cells. However, PI3K/mTOR inhibition also resulted in decreased migratory rates, indicating that both pathways were related to inhibition of the migratory ability of these cells. To investigate whether this also had consequences for the metastatic properties, a zebrafish xenograft experiment was performed.

For these experiments, we used dasatinib as a cSRC inhibitor and everolimus as a PI3K/mTOR inhibitor because these compounds have also been used in human clinical trials.\(^30,68\) Cell viability and incidence of metastases were strongly reduced after pre-treatment of CMT-U27 cells with dasatinib followed by injection in the yolk sac or in the duct of Cuvier of zebrafish larvae. When cells were pre-treated with 10 μM everolimus and then injected into the yolk or duct of Cuvier larvae, survival was good, but in contrast with dasatinib, it resulted in an increased incidence of metastasis. The fact that no decrease in metastasis but rather a limited increase was observed was consistent with our findings that everolimus further upregulated the already high basal Wnt activity.\(^20\)

It is concluded that the highly activated Wnt signalling in the CMT-U27 canine mammary cell line, which is similar to human HER2-overexpressing luminal cell lines, is not related to HER2/3 signalling. Additionally, no relation was observed between HER proteins and cSRC activation. Inhibition of PI3K/mTOR activity due to HER signalling and loss of PTEN expression was associated with enhanced metastasis in a zebrafish xenograft model.

The cSRC inhibitor dasatinib decreased Wnt signalling, migration and metastasis. The fact that the cSRC inhibitor dasatinib was effective in decreasing metastasis of our HER2\(^*\) and PTEN\(^*\) CMT-U27 cells makes it worthwhile to further evaluate this drug for the treatment of patients with this type of breast cancer because PTEN loss has been associated with a worse outcome in HER2-amplified human breast cancer patients.\(^69\) Because human breast cancer patients have already been treated with dasatinib in a phase II study,\(^70,71\) it may be of interest to relate the clinical outcome to data on HER and Wnt signalling.

ACKNOWLEDGEMENTS

We greatly acknowledge the help of Richard Wubbolts and Heiko Henning from the Utrecht University Center for Cell Imaging for technical assistance with imaging.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

REFERENCES

1. Liu D, Xiong H, Ellis AE, et al. Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer. Cancer Res. 2014;74(18):5045-5056.
2. Campbell EJ, Tesson M, Doogan F, Mohammed ZMA, Mallon E, Edwards J. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone. Br J Cancer. 2016;115(8):967-973.
3. Clark GM, McGuire WL. Prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1983;3 Suppl:S69-S72.
4. Pena L, Gama A, Goldschmidt MH, et al. Canine mammary tumors: a review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry. Vet Pathol. 2014;51(1):127-145.
5. Martin PM, Tomita M, Mialot JP, Andre F, Raynaud JP. Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate. Cancer Chemother Pharmacol. 1984;12(1):13-17.
6. Toniti W, Buranasinsup S, Kongcharoen A, Charoonrut P, Puchadapirom P, Kasomdorkova C. Immunohistochemical determination of estrogen and progesterone receptors in canine mammary tumors. Asian Pac J Cancer Prev. 2009;10(5):907-911.
7. Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L. Coping with uncertainty: T1N0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol. 2011;22(11):2387-2393.
8. Templeton A, Ocana A, Seruga B, et al. Management of small HER2 overexpressing tumours. Breast Cancer Res Treat. 2012;136(1):289-293.
9. Tryfonidis K, Zardavas D, Katzenellenbogen BS, Piccart M. Endocrine treatment in breast cancer: cure, resistance and beyond. Cancer Treat Rev. 2016;50:68-81.
10. Jhan JR, Andrecheek ER. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics. 2017;18(17):1595-1609.
11. Andrulis IL, Bull SB, Blackstein ME, et al. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto breast cancer study group. J Clin Oncol. 1998;16(4):1340-1349.
12. Agosto-Arroyo E, Isayeva T, Wei S, Almeida JS, Harada S. Differential gene expression in ductal carcinoma in situ of the breast based on ERBB2 status. Cancer Control. 2017;24(1):102-110.
13. Latta EK, Tjan S, Parkes RK, O’Malley FP. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 2002;15(12):1318-1325.
14. Jeon M, You D, Bae SY, et al. Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction. Oncotarget. 2016;8(31):50570-50581.
15. Lin SY, Xia W, Wang JC, et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A. 2000;97(8):4262-4266.
16. Howe LR, Brown AMC. Wnt signaling and breast cancer. Cancer Biol Ther. 2004;3(1):36-41.
17. Li S, Li S, Sun Y, Li L. The expression of β-catenin in different subtypes of breast cancer and its clinical significance. Tumour Biol. 2014;35(8):7693-7698.
18. Schade B, Lesurf R, Sanguin-Gendreau V, et al. Beta-catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. Cancer Res. 2013;73(14):4474-4487.

19. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469-6487.

20. Timmermans-Sprang EP, Gracanin A, Mol JA. High basal Wnt signaling is further induced by PI3K/mTOR inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression. BMC Cancer. 2015;15:545. https://doi.org/10.1186/s12885-015-1544-y.

21. Mohammed SI, Meloni GB, Pinna Parpaglia MLP, et al. Mammmography and ultrasound imaging of preinvasive and invasive canine spontaneous mammary cancer and their similarities to human breast cancer. Cancer Prev Res (Phila). 2011;4(11):1790-1798.

22. Chen YC, Chen YY, Liao JW, Chang SC. Expression and prognostic value of c-met in canine mammary tumours. Vet Comp Oncol. 2018;16(4):670-676.

23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-664.

24. Gracanin A, Timmermans-Sprang EPM, van Wolferen ME, et al. Ligand-independent canonical Wnt activity in canine mammary tumor cell lines associated with aberrant LEF1 expression. PLoS One. 2014;9(6):e98698.

25. Kuphal F, Behrens J. E-cadherin modulates Wnt-dependent transcription in colorectal cancer cells but does not alter Wnt-independent gene expression in fibroblasts. Exp Cell Res. 2006;312(4):457-467.

26. Timmermans-Sprang EPM, Gracanin A, Mol JA. Molecular signaling of progesterone, growth hormone, Wnt, and HER in mammary glands of dogs, rodents, and humans: new treatment target identification. Front Vet Sci. 2017;4:53.

27. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15(2):117-134.

28. Liu X, Feng R. Inhibition of epithelial to mesenchymal transition in metastatic breast carcinoma cells by c-Src suppression. Acta Biochim Biophys Sin (Shanghai). 2010;42(7):496-501.

29. Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. Int J Clin Exp Pathol. 2015;8(6):6143-6156.

30. McKnight BN, Viola-Villegas NT. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging. Breast Cancer Res. 2018;20(1):130. https://doi.org/10.1186/s13058-018-1055-2.

31. Glasser S, Bolton LM, Johnson P, Torrance C, Cree IA. Activity of EGF-R, mTOR and PI3K inhibitors in an isogenic breast cell line model. BMC Res Notes. 2014;7:397. https://doi.org/10.1186/1756-0500-7-397.

32. Al Masri A, Gendler SJ. Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis. Oncogene. 2005;24(38):5799-5808.

33. Kim H, Chan R, Dankort DL, et al. The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. Oncogene. 2005;24(51):7599-7607.

34. Ghotra VPS, He S, de Bont H, et al. Automated whole animal bioimaging assay for human cancer dissemination. PLoS One. 2012;7(2):e31281.

35. Drabsh Y, He S, Zhang L, Snaar-Jagalska BE, ten Dijke P. Transforming growth factor-β signalling controls human breast cancer metastasis in a zebrafish xenograft model. Breast Cancer Res. 2013;15(6):R106.

36. Buishand FO, Arkesteijn GJ, Feenstra LR, et al. Identification of CD90 as putative cancer stem cell marker and therapeutic target in Insulonomas. Stem Cells Dev. 2016;25(11):826-835.

37. Hellmen E. Characterization of four in vitro established canine mammary carcinoma and one atypical benign mixed tumor cell lines. In Vitro Cell Dev Biol. 1992;28A(5):309-319.

38. Van Leeuwen IS, Hellmen E, Cornelisse CJ, Van den Burgh B, Rutteman GR. P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog. Anticancer Res. 1996;16(6B):3737-3744.

39. Uyama R, Nakagawa T, Hong SH, Mochizuki M, Nishimura R, Sasaki N. Establishment of four pairs of canine mammary tumour cell lines derived from primary and metastatic origin and their E-cadherin expression. Vet Comp Oncol. 2006;4(2):104-113.

40. Gui-Luna S, Hellmen E, Sanchez-Cespedes R, Millan Y, Martin de las Malas J. The antiangiogenic mifepristone and onapristone reduce cell proliferation in the canine mammary carcinoma cell line CMT-U27. Histol Histopathol. 2014;29(7):949-955.

41. Kohl M. SlqPCR: Functions for Analysis of Real-Time Quantitative PCR Data at SIRS-Lab GmbH. 2007.

42. Team RC. R: A Language and Environment for Statistical Computing. 2016. https://www.rstudio.com/.

43. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔCT) method. Methods. 2001;25(4):402-408.

44. Doleschall M, Mayer B, Cervenak J, Cervenak L, Kacskovics I. Cloning, expression and characterization of the bovine p65 subunit of NFκappAB. Dev Comp Immunol. 2007;31(9):945-961.

45. Truong HH, Xiong J, Ghotra VPS, et al. beta1 integrin inhibition elicits a prometastatic switch through the TGFbeta-mir-200-ZEB network in E-cadherin-positive triple-negative breast cancer. Sci Signal. 2014;7(312):ra15.

46. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol. 2002;248(2):307-318.

47. Sabaawy HE, Azuma A, Embrey LJ, Tsai HJ, Starost MF, Hickstt DD. TEL-AML1 transgenic zebrafish model of precursor B acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2006;103(41):15166-15171.

48. Nantasanti S, Spee B, Kruitwagen HS, et al. Disease modeling and gene therapy of copper storage disease in canine hepatic organoids. Stem Cell Reports. 2015;5(5):895-907.

49. Eguiara A, Holgado O, Beloqui I, et al. Xenografts in zebrafish embryos as a rapid functional assay for breast cancer stem-like cell identification. Cell Cycle. 2011;10(21):3751-3757.

50. Tulotta C, He S, van der Ent W, et al. Imaging cancer angiogenesis and metastasis in a zebrafish embryo model. Adv Exp Med Biol. 2016;916:239-263.

51. Brown HK, Schiavone K, Hickstt DD, TEL-AML1 transgenic zebrafish model of precursor B acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2016;103(41):15166-15171.

52. Team RC. R: A Language and Environment for Statistical Computing. 2016. https://www.rstudio.com/.

53. Nishimura Y, Inoue A, Sasagawa S, et al. Using zebrafish in systems toxicology for developmental toxicity testing. Congenit Anom (Kyoto). 2016;56(1):18-27.

54. Cazanjian ME, Airolidi M, Arcangeli V, et al. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: new insights beyond clinical trials. The EVA study. Breast. 2017;35:115-121.

55. Somlo G, Atzori F, Strauss LC, et al. Dasatinib plus capecitabine for advanced breast cancer patients: new insights beyond clinical trials. The EVA study. Breast. 2017;35:115-121.

56. Wang Z, Li B, Zhou L, et al. Prodiginin inhibits Wnt/beta-catenin signaling and exerts anticaner activity in breast cancer cells. Proc Natl Acad Sci U S A. 2016;113(46):13150-13155.
57. Jho EH, Zhang T, Domon C, Joo CK, Freuden JD, Costantini F. Wnt/-beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 2002;22(4):1172-1183.

58. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463-475.

59. Lee-Hoeft ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68(14):5878-5887.

60. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297-315.

61. Geuna E, Montemurro F, Aglietta M, Valabrega G. Potential of afatinib in the treatment of patients with HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2012;4:131-137.

62. Yokoyama N, Malbon CC. Dishevelled-2 docks and activates Src in a Wnt-dependent manner. J Cell Sci. 2009;122(24):4439-4451.

63. Gao C, Chen YG. Dishevelled: the hub of Wnt signaling. Cell Signal. 2010;22(5):717-727.

64. Couffinhal T, Dufourcq P, Duplaa C. Beta-catenin nuclear activation: common pathway between Wnt and growth factor signaling in vascular smooth muscle cell proliferation? Circ Res. 2006;99(12):1287-1289.

65. Kari R, Gus Y, Dor Y, Meyuhas O, Levitzki A. Active Src elevates the expression of beta-catenin by enhancement of cap-dependent translation. Mol Cell Biol. 2005;25(12):5031-5039.

66. Fonte C, Grenier J, Trousson A, et al. Involvement of (beta)-catenin and unusual behavior of CBP and p300 in glucocorticosteroid signaling in Schwann cells. Proc Natl Acad Sci U S A. 2005;102(40):14260-14265.

67. Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 2014;35(8):7335-7342.

68. Van Swearingen AED, Siegel MB, Deal AM, et al. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Res Treat. 2018;171(3):637-648.

69. Stern HM, Gardner H, Burzykowski T, et al. PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with Trastuzumab resistance. Clin Cancer Res. 2015;21(9):2065-2074.

70. Ocana A, Gil-Martin M, Martin M, et al. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GECAM/2010-04 study. Oncotarget. 2017;8:73144-73153.

71. Stanley A, Ashrafi GH, Seddon AM, Modjtabahi H. Synergistic effects of various her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. Sci Rep. 2017;7(1):3964. https://doi.org/10.1038/s41598-017-04301-8.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Timmermans-Sprang EPM, Mestemaker HM, Steenlage RR, Mol JA. Dasatinib inhibition of cSRC prevents the migration and metastasis of canine mammary cancer cells with enhanced Wnt and HER signalling. Vet Comp Oncol. 2019;17:413–426. https://doi.org/10.1111/vco.12490